Wellington Management Group LLP decreased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 1.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,309,987 shares of the company’s stock after selling 24,822 shares during the period. Wellington Management Group LLP’s holdings in Mirum Pharmaceuticals were worth $153,360,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Empowered Funds LLC bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at $229,000. Jefferies Financial Group Inc. bought a new stake in Mirum Pharmaceuticals during the 2nd quarter worth $4,596,000. Seven Fleet Capital Management LP bought a new stake in Mirum Pharmaceuticals during the 2nd quarter worth $12,924,000. Corient Private Wealth LP acquired a new position in Mirum Pharmaceuticals in the 2nd quarter worth about $1,565,000. Finally, Bank of America Corp DE acquired a new position in Mirum Pharmaceuticals in the 2nd quarter worth about $65,761,000.
Insider Transactions at Mirum Pharmaceuticals
In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 20,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $23,758,161.43. This represents a 9.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the sale, the senior vice president owned 1,274 shares of the company’s stock, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 103,156 shares of company stock worth $10,888,362. Company insiders own 8.32% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Stock Up 0.6%
Shares of MIRM opened at $98.05 on Tuesday. The stock’s 50-day moving average price is $110.44 and its two-hundred day moving average price is $101.78. Mirum Pharmaceuticals, Inc. has a 12 month low of $63.23 and a 12 month high of $130.00. The company has a market capitalization of $6.37 billion, a PE ratio of -6.74 and a beta of 0.52. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. During the same quarter last year, the business earned ($0.12) earnings per share. Mirum Pharmaceuticals’s revenue was up 37.9% compared to the same quarter last year. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Recommended Stories
- Five stocks we like better than Mirum Pharmaceuticals
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
